Summary
Medtronic plc (MDT) announced on December 15, 2021, that it received a warning letter from the U.S. Food and Drug Administration (FDA) concerning its Northridge, California facility. While the company is actively addressing the FDA's concerns and working towards comprehensive resolutions, this development has led to revised revenue expectations specifically for its Diabetes business. Medtronic now anticipates a high-single digit decline for its Diabetes business in the third fiscal quarter and a mid-single digit decline for the full fiscal year 2022. This represents a downward revision from previous guidance. Importantly, the company currently does not expect this issue to materially impact its overall total company organic revenue growth and adjusted earnings per share guidance for fiscal year 2022. However, potential impacts on fiscal year 2023 revenue growth are being modeled, with preliminary estimates ranging from less than 0.5 percentage points to approximately 1 percentage point of growth reduction, depending on various scenarios.
Key Highlights
- 1Medtronic received a warning letter from the FDA following an inspection of its Northridge, California facility.
- 2The company is actively addressing the FDA's concerns and working on comprehensive corrective actions.
- 3The warning letter is expected to negatively impact Medtronic's Diabetes business revenue.
- 4Revised guidance for the Diabetes business now projects a high-single digit decline for Q3 FY22 and a mid-single digit decline for FY22.
- 5Medtronic currently forecasts no impact on total company organic revenue growth and adjusted EPS guidance for FY22.
- 6Preliminary estimates suggest a potential FY23 revenue growth impact of 0.5 to 1 percentage point, with full guidance to be provided in May 2022.
- 7Uncertainty regarding U.S. Diabetes product approvals is cited as a factor in the revised Diabetes business outlook.